PSFS Building

Mobile in Clinical Trials® 2024 Reports on Supporting More Patients to Participate Remotely in Clinical Trials While Demonstrating ROI organized by the Conference Forum

Retrieved on: 
목요일, 6월 13, 2024
Conference, PSFS Building, ChromeOS, Advocacy, ROI, Clinical trial, MPH, Patient, Research, Pharmaceutical industry

NEW YORK, June 13, 2024 /PRNewswire-PRWeb/ -- The Conference Forum announced today the launch of the 11th annual Mobile in Clinical Trials® conference, taking place Sep 16, 2024 at the Loews Philadelphia Hotel in Philadelphia, PA.

Key Points: 
  • The Conference Forum announced the launch of the 11th annual Mobile in Clinical Trials® event, focused on the ROI of the implementation of mobile and digital technologies from pharma, sites and CROs to enable more patients to participate remotely.
  • NEW YORK, June 13, 2024 /PRNewswire-PRWeb/ -- The Conference Forum announced today the launch of the 11th annual Mobile in Clinical Trials® conference, taking place Sep 16, 2024 at the Loews Philadelphia Hotel in Philadelphia, PA.
    "Mobile and digital technologies in clinical trials can play a significant role in expediting research in clinical trials by allowing more patients to participate remotely."
  • Kate Woda, Senior Director, Mobile in Clinical Trials®
    "Mobile and digital technologies in clinical trials can play a significant role in expediting research in clinical trials by allowing more patients to participate remotely," said Kate Woda, Senior Director, Mobile in Clinical Trials®.
  • The 2024 Mobile in Clinical Trials® will address:
    "This industry is at a pivotal point; to maximize ROI, it is imperative companies hold themselves to high patient-centric standards.

DPHARM® Launches 2024 Event Addressing Innovation to Manage Clinical Trials Complexity, Capabilities Gaps and Costs Organized by the Conference Forum

Retrieved on: 
목요일, 6월 13, 2024
Drug development, MBE, Trial, Corporation, DevOps, Automation, Pharma, Patient, PSFS Building, MBA, Risk management, Biogen, Culture, Portfolio management, Head, Doctor of Philosophy, Analytics, Clinical trial, AI, Novo Nordisk, Organization, PMP, Conference, US Airways Flight 1549, Regeneron Pharmaceuticals, Medicine, SVP, Cell, Oncology, US Airways, Management

NEW YORK, June 13, 2024 /PRNewswire-PRWeb/ -- The Conference Forum announced today the launch of the 14th annual DPHARM: Disruptive Innovations to Modernize Clinical Research conference, taking place September 17-18, 2024, at the Loews Philadelphia Hotel in Philadelphia, PA.

Key Points: 
  • The Conference Forum announced the launch of the 14th annual DPHARM®: Disruptive Innovations to Modernize Clinical Research's agenda, with the focus on innovating to manage complexity, capabilities gaps and costs.
  • "Carefully guided by 50 clinical operations leaders, this year's DPHARM agenda gets granular on how to respond to the increasing complexity in the clinical trials landscape and strategically deploying AI and GenAI."
  • said Tracey Kimball, DPHARM Conference Director, Conference Forum.
  • "The focus on exploring innovative approaches to effectively manage the complexities, bridge capability gaps, and optimize costs within the pharmaceutical industry is crucial for driving industry progress, enhancing operational efficiency, and fostering a culture of continuous improvement.

4 Greenberg Traurig Attorneys in Delaware, Philadelphia Recognized by ALM

Retrieved on: 
화요일, 4월 2, 2024
Employment, Delmarva Peninsula, Labour, Child, Associate, Big Brothers Big Sisters, Fast Track, ALM, Lawyer, LLP, PSFS Building, Volunteering, Unsung Heroes, Intellectual property, Book, Nursing

NEW YORK, April 2, 2024 /PRNewswire-PRWeb/ -- Global law firm Greenberg Traurig, LLP Shareholders Diane N. Ibrahim, Samuel L. Moultrie, and Shira R. Yoshor, and Associate Renée Mosley Delcollo will be recognized at the 2024 Pennsylvania Legal Awards (PALA), sponsored by ALM's Legal Intelligencer. Honorees will be recognized at the awards celebration May 15 at the Loews Philadelphia Hotel.

Key Points: 
  • Honorees will be recognized at the awards celebration May 15 at the Loews Philadelphia Hotel.
  • Honorees will be recognized at the awards celebration May 15 at the Loews Philadelphia Hotel.
  • Yoshor, a Labor & Employment Practice shareholder in the Philadelphia office , is a finalist for "2024 Best Law Firm Mentor."
  • As the Career Development Liaison previously in Houston and now in Philadelphia, she has been involved in mentoring lawyers extensively since she joined Greenberg Traurig.

Jill Roth of Laffey, Bucci & Kent Named Among 'Lawyers on the Fast Track' by The Legal Intelligencer

Retrieved on: 
월요일, 3월 25, 2024
Crime, Legislation, University, Personal injury, Abuse, DA, Domestic violence, Fast Track, The Legal Intelligencer, Lawyer, Hospital, PSFS Building, Internet, District Attorney of Philadelphia, Survivor, Rape, Intimidation, Multimedia, Commonwealth, Property management

PHILADELPHIA, March 25, 2024 /PRNewswire-PRWeb/ -- Personal injury law firm Laffey, Bucci & Kent is pleased to announce that victims' advocate Jill Roth has been named among the Lawyers on the Fast Track in the small/midsize firms category by The Legal Intelligencer. This recognition is part of the publication's 2024 Pennsylvania Legal Awards, which highlight great work and achievements across the full breadth of the legal communities in Pennsylvania and Delaware.

Key Points: 
  • "We congratulate Jill on this well-deserved recognition of her deeply impactful work on behalf of victims of crime," said Jeff Laffey, Co-Managing Partner.
  • Roth is currently defending a client from a frivolous lawsuit filed by social media influencer Andrew Tate seeking $5 million.
  • "I am grateful to be recognized by The Legal Intelligencer and my colleagues in the Pennsylvania legal community for my work in support of survivors," said Roth.
  • Laffey, Bucci & Kent was founded in 2009 by Jeff Laffey, Paul Bucci & Brian Kent.

Infotel Announces Sponsorship and Speaking Engagement at 2023 IDUG North America Db2 for IBM z/OS Tech Conference

Retrieved on: 
수요일, 5월 10, 2023
Database, IBM, Education, Face, Culture, NA, PSFS Building, DB2 SQL return codes, DBA, Automation, Certification, Organization, Z/OS, Partner, Control, Conference, PSP, Software, Video game, IBM Db2, Jio

TAMPA, Fla., May 10, 2023 /PRNewswire-PRWeb/ -- Tampa-based global software vendor and IT consulting firm Infotel Corp. today announced its sponsorship of the 2023 IDUG North America Db2 Tech Conference in Philadelphia, May 15-19. Infotel will also be sponsoring a Partner Sponsored Presentation (PSP) with global Db2 expert Craig S. Mullins and Infotel's senior technical manager Thierry Hubert on intelligent automation for Db2. Hubert's portion of the PSP will feature a Db2 automation use case from one of Infotel's customers.

Key Points: 
  • Global leader in mainframe software Infotel Corp. to sponsor IDUG® NA Db2 Tech Conference in Philadelphia.
  • TAMPA, Fla., May 10, 2023 /PRNewswire-PRWeb/ -- Tampa-based global software vendor and IT consulting firm Infotel Corp. today announced its sponsorship of the 2023 IDUG North America Db2 Tech Conference in Philadelphia, May 15-19.
  • "The Infotel team is thrilled to once again attend the 2023 IDUG North American Db2 Tech Conference, held this year in Philadelphia," said Jeff Castella, Infotel Corp's vice president of software.
  • Visit https://go.insoft-infotel.com/idug-na-2023-lp to subscribe to Infotel content in North America and to receive a link to the Infotel PSP slide deck.

Ashvattha Therapeutics Announces Presentation of Preclinical Data at the 2022 Neurofibromatosis (NF) Conference Demonstrating the Potential of Hydroxyl Dendrimer Therapeutics to Reduce Toxicity in Targeted Treatment of Plexiform Neurofibroma

Retrieved on: 
화요일, 6월 21, 2022
NF1, Skin, American Academy, Lists of diseases, Therapy, Pediatrics (journal), Microglia, Safety, Neurofibromatosis type I, Tumor-associated macrophage, Neuron, HDT, Technology, HD, Tumor microenvironment, Inherited disorders of trafficking, CEO, Diabetic retinopathy, Toxicity, Johns Hopkins University, Indiana University School of Medicine, HDS, Brain, AMD, Neuro, Inflammation, Ophthalmology, Neurofibroma, Growth, Disease, Neurofibromatosis, TME, Ashvattha, Dendrimer, DME, NF, Patient, Neoplasm, Pigment, Conference, Macrophage, Neurology, GLOBE, PNF, Tams, PSFS Building, Pharmaceutical industry

The data was presented by Emma C. Mazurek, a scientific collaborator at Indiana University School of Medicine, in a poster titled, Hydroxyl Dendrimer Therapeutics Reduce Toxicity in Targeted Delivery to Plexiform Neurofibroma.

Key Points: 
  • The data was presented by Emma C. Mazurek, a scientific collaborator at Indiana University School of Medicine, in a poster titled, Hydroxyl Dendrimer Therapeutics Reduce Toxicity in Targeted Delivery to Plexiform Neurofibroma.
  • Notably, the smaller HD (~14 kDa) showed greater uptake in tumor associated macrophages and microglia, than the larger HD (~56 kDa).
  • These results suggest that by conjugating drugs to HDs theres potential to improve safety and reduce toxicity associated with current treatments for NF.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, ophthalmology, inflammatory diseases and neuro-oncology.

Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based Therapeutics at the 2022 Neurofibromatosis (NF) Conference

Retrieved on: 
화요일, 6월 7, 2022
Neurofibromatosis, HDS, PSFS Building, Conference, Toxicity, Johns Hopkins University, Inflammation, NF, Disease, Neurofibromatosis type I, AMD, Therapy, Diabetic retinopathy, NF1, Neuro, HDT, Ophthalmology, GLOBE, Neurology, Technology, COVID-19, DME, Ashvattha, Pharmaceutical industry

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (Ashvattha), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma, a slow growing tumor associated with neurofibromatosis type 1 (NF1), at the 2022 Neurofibromatosis (NF) Conference hosted by the Childrens Tumor Foundation and taking place at Loews Philadelphia Hotel in Philadelphia, PA, June 18 21, 2022.

Key Points: 
  • REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (Ashvattha), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma, a slow growing tumor associated with neurofibromatosis type 1 (NF1), at the 2022 Neurofibromatosis (NF) Conference hosted by the Childrens Tumor Foundation and taking place at Loews Philadelphia Hotel in Philadelphia, PA, June 18 21, 2022.
  • Poster presentation details can be found below:
    Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, ophthalmology, inflammatory diseases, and neuro-oncology.
  • The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University.
  • HDs chemically conjugated to disease modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects.